Gilead Sciences
Trade Gilead Sciences 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About GILD
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.
GILD Key Statistics
Stock Snapshot
The current Gilead Sciences(GILD) stock price is $156.33, with a market capitalization of 193.84B. The stock trades at a price-to-earnings (P/E) ratio of -57.81 and offers a dividend yield of 2.12%.
During the trading session on 2026-10-22, Gilead Sciences(GILD) shares reached a daily high of $156.51 and a low of $153.00. At a current price of $156.33, the stock is +2.2% higher than the low and still -0.1% under the high.
Trading activity shows a volume of 918.27K, compared to an average daily volume of 6.23M.
Over the past 52 weeks, Gilead Sciences(GILD) stock has traded between a high of $160.51 and a low of $114.02.
Over the past 52 weeks, Gilead Sciences(GILD) stock has traded between a high of $160.51 and a low of $114.02.
GILD News
Gilead (GILD) Sciences will present new clinical and real-world evidence across primary biliary cholangitis, PBC, and chronic hepatitis delta virus, HDV, infect...
...
BioNTech (BNTX) announced a clinical trial collaboration and supply agreement with Gilead Sciences (GILD) to evaluate pumitamig in combination with the TROP2-di...
Analyst ratings
77%
of 30 ratingsMore GILD News
Gilead Sciences (GILD Quick QuoteGILD - Free Report) closed at $153.57 in the latest trading session, marking a -1.88% move from the prior day. The stock...
Gilead Sciences, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Tazeen Ahmad from Bank of America Securities reiterate...
Gilead Sciences Inc. (NASDAQ:GILD) on Monday announced 12-week induction data from its Phase 2 SWIFT trial evaluating emvistegrast, an investigational once-dail...
Gilead (GILD) Sciences taking place October 21-24 in Washington, D.C. The 28 presentations, including two oral presentations, will feature research in HIV treat...
Fresh regulatory decisions have put Gilead Sciences (GILD) back in focus for investors, following approvals for HIV therapy Bixlenvo, an expanded Trodelvy cance...
Gilead Sciences (GILD -0.75%), a biotech leader, has outperformed broader equities this year. The company's financial results have been fairly strong, contribut...
Gilead Sciences recently announced a collaboration and license agreement with Vir Biotechnology to develop dual masked T cell engager drugs targeting solid tumo...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.